Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma

Haematologica

Volumn 92, Issue 11, 2007, Pages 1505-1512

  Dimopoulos, Meletios A ^a,d   Souliotis, Vassilis L ^b   Anagnostopoulos, Athanasios ^a   Bamia, Christina ^a   Pouli, Anastasia ^c   Baltadakis, Ioannis ^c   Terpos, Evangelos ^d   Kyrtopoulos, Soterios A ^b   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

^c Greek Myeloma Study Group   (Greece)

^d NONE

Author keywords

In vitro induced adducts; Melphalan; Multiple meyloma; p53 specific damage formation repair; Prediction of clinical outcome

Indexed keywords

DNA; MELPHALAN; NUCLEOTIDE; PROTEIN P53;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; FEMALE; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROTEIN CROSS LINKING; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; DNA DAMAGE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 36348975835     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11435     Document Type: Article

References (29)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-73.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-7.
3. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy: final results of Phase III US Intergroup Trial S9321 for Multiple Myeloma. J Clin Oncol 2006;24:929-36.
4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83.
5. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med 2003;348:2609-17.
6. Richardson PG, Schlossman RL, Weiler E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
7. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
8. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72.
9. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
10. Sunters A, Springer CJ, Bagshawe KD, Souhami RL, Hartley JA. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 1992;44:59-64.
11. Dronkert ML, Kanaar R. Repair of DNA interstrand cross-links. Mutat Res 2001;486:217-47.
12. Grant DF, Bessho T, Reardon JT Nucleotide excision repair of melphalan monoadducts. Cancer Res 1998;58:5196-200.
13. Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair 2006;5:972-85.
14. Moscow JA, Swanson CA, Cowan KH. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 1993;68:732-7.
15. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984;44:5427-31.
16. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813-5.
17. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34:9-19.
18. Tan KB, Mattern MR, Boyce RA, Hertzberg RP, Schein PS. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. NCI Monogr 1987;4:95-8.
19. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224-9.
20. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-50.
21. Sasaki MS, Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973;33:1829-36.
22. Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000; 14:1400-6.
23. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705.
24. Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 2003;9:4465-74.
25. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 2005;23:4381-9.
26. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
27. Hansson J, Lewensohn R, Ringborg U, Nilsson B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 1987;47:2631-7.
28. Bohr VA, Phillips DH, Hanawalt PC. Heterogeneous DNA damage and repair in the mammalian genome. Cancer Res 1987;47:6426-36.
29. Oshita F, Saijo N. Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines. Jpn J Cancer Res 1994;85:669-73.